Recent breakthroughs illustrate AI’s expanding role in oncology, with institutions developing models for early cancer detection and enhanced diagnostic accuracy. The University of Sharjah unveiled AI tools for early-stage pancreatic cancer prediction, while Adaptive Biotechnologies integrated its ClonoSeq minimal residual disease assay into Flatiron Health’s EMR, streamlining access for community oncologists. Additionally, NYU Tandon developed an immunocompetent leukemia-on-a-chip model supporting CAR T therapy screening, underscoring AI’s transformative potential in personalized medicine and therapeutic development.